Francisella tularensis: Difference between revisions
From IDWiki
Francisella tularensis
No edit summary |
No edit summary |
||
Line 39: | Line 39: | ||
**Inhalation of aerosolized vectors (e.g. lawn-mowing), contact with contaminated water or mud, and animal bites of animals that have killed infected reservoir hosts (e.g. cats killing rodents) |
**Inhalation of aerosolized vectors (e.g. lawn-mowing), contact with contaminated water or mud, and animal bites of animals that have killed infected reservoir hosts (e.g. cats killing rodents) |
||
=== |
===Pathophysiology=== |
||
* |
*Infectious dose depends on route, but is as low as 10 to 50 organisms when injected intradermally or inhaled (or several orders of magnitude higher if ingested) |
||
* |
*[[Toll-like receptors|TLR4]] has less affinity for its LPS compared to other bacteria |
||
* |
*Capsule inhibits IgM and complement C3 |
||
** |
**Capsule-deficient strains are both less immunogenic and less virulent |
||
* |
*Facultative intracellular growth |
||
** |
**Can infect and persist within erythrocytes, providing protection against [[aminoglycosides]] |
||
==Clinical Manifestations== |
==Clinical Manifestations== |
||
Line 57: | Line 57: | ||
**May have a [[Causes::relative bradycardia]] (more common in US than Europe) |
**May have a [[Causes::relative bradycardia]] (more common in US than Europe) |
||
*These symptoms may remit and relapse, presenting as a subacute [[Causes::relapsing fever]] over weeks, with associated weight loss, deconditioning, and lymphadenopathy |
*These symptoms may remit and relapse, presenting as a subacute [[Causes::relapsing fever]] over weeks, with associated weight loss, deconditioning, and lymphadenopathy |
||
⚫ | |||
=== Ulceroglandular Tularemia === |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
=== Glandular Tularemia === |
|||
⚫ | |||
⚫ | |||
=== Oculoglandular Tularemia === |
|||
⚫ | |||
*Rare |
|||
=== Pharyngeal Tularemia === |
|||
⚫ | |||
*May be difficult to distinguish from other forms of tularemia that also may have sore throat |
|||
=== Typhoidal Tularemia === |
|||
⚫ | |||
*Patient often has an underlying chronic disease |
|||
*Often rapidly-progressive and fatal |
|||
=== Pneumonic Tularemia === |
|||
⚫ | |||
==Diagnosis== |
==Diagnosis== |
||
Line 82: | Line 104: | ||
**Aminoglycosides have poor CNS penetration |
**Aminoglycosides have poor CNS penetration |
||
== |
==Prevention== |
||
=== |
===Vaccination=== |
||
* |
*Live attenuated vaccine derived from ''holarctica'' |
||
=== |
===Lab Safety=== |
||
* |
*This is a [[Biosafety risk groups|biosafety risk group]] 3 organism |
||
* |
*Should be suspected with any slowly-growing, small, and poorly-staining Gram-negative coccobacillus is isolated on chocolate agar but not blood agar |
||
* |
*Automated laboratory identification systems should ''not'' be used, because the risk of aerosol generation |
||
* |
*Commonly misidentified by automated methods as [[Haemophilus species|Haemophilus]] or [[Aggregatibacter]] species |
||
{{DISPLAYTITLE:''Francisella tularensis''}} |
{{DISPLAYTITLE:''Francisella tularensis''}} |
||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
Revision as of 09:22, 3 September 2020
- Zoonontic infection carried on rodents and rabbits and transmitted by biting insects
- Presentation depends on route of entry: (ulcero)glandular, oculoglandular, pharyngeal, typhoidal, or pneumonic
- Treatment is streptomycin
Background
Microbiology
- A fastidious Gram-negative coccobacillus
- Multiple subspecies, including tularensis, holarctica, novocida, mediasiatica, which are further subdivided into clades, and related species Francisella philomiragia and Francisella hispaniensis
- Subspecies of importance to humans include:
- Subspecies tularensis (type A strains)
- Found in North America and rarely Europe
- Two major clades (AI and AII) and four subclades (AIa, AIb, AIIa, and AIIb)
- Overall the subspecies is the most virulent subspecies, and specifically the AIb subclade is the most virulent strain
- Subspecies holarctica (type B strains)
- Found in the entire northern hemisphere as well as Australia
- Four major clades (B4 in North America, B6 in Western Europe, B12 in Eastern Europe and Central Asia, and B16 in Japan and other areas in Eastern Asia) and a number of subclades
- Subspecies novicida
- Rare cause of disease in humans, usually in immunocompromised hosts, and presents with bacteremia rather than tularemia
- Subspecies mediasiatica does not cause disease in humans
- Subspecies tularensis (type A strains)
History
- Discovered in 1911 in Tulare county, California
- Many names: deer fly fever, rabbit fever, etc...
Epidemiology
- Zoonotic infection whose main animal reservoirs are rodents and rabbits
- In North America, the most important reservoirs are Sylvilagus species (especially Sylvilagus nuttalii, the cottontail rabbit) and Lepus species lagomorphs (rabbits), and a number of rodents including voles, squirrels, muskrats, and beavers
- In Europe, the reservoirs include voles, hamsters, mice, and hares
- Essentially worldwide Northern Hemisphere distribution, especially in the US, Japan, Russia, and Scandinavian countries
- Transmission:
- Vector-borne
- In North America, by Amblyomma americanum ticks, Dermacentor variabilis ticks, Dermacentor andersoni ticks, Chrysops discalis deer flies
- In Europe, Aedes cinereus and Ochlerotatus exrucians mosquitoes are more important, as well as Chrysops relictus deer flies and Haematopota pluvialis horse flies
- Direct contact with animal products, including skinning, dressing, and eating wild game
- Viable in carcasses and dust for up to 136 days
- Inhalation of aerosolized vectors (e.g. lawn-mowing), contact with contaminated water or mud, and animal bites of animals that have killed infected reservoir hosts (e.g. cats killing rodents)
- Vector-borne
Pathophysiology
- Infectious dose depends on route, but is as low as 10 to 50 organisms when injected intradermally or inhaled (or several orders of magnitude higher if ingested)
- TLR4 has less affinity for its LPS compared to other bacteria
- Capsule inhibits IgM and complement C3
- Capsule-deficient strains are both less immunogenic and less virulent
- Facultative intracellular growth
- Can infect and persist within erythrocytes, providing protection against aminoglycosides
Clinical Manifestations
- Incubation period of 3 to 5 days (range 1 to 21 days)
- The first symptom is usually a papule at the site of inoculation that develops into an ulcer over 1 to 2 days, but this may go unnoticed
- This is followed by fever which likely corresponds to initial lymphohematogenous dissemination
- Other common symptoms include chills, headache, malaise, anorexia, and fatigue
- May also have cough, myalgias, chest discomfort, vomiting, sore throat, abdominal pain, and diarrhea
- May have a relative bradycardia (more common in US than Europe)
- These symptoms may remit and relapse, presenting as a subacute relapsing fever over weeks, with associated weight loss, deconditioning, and lymphadenopathy
Ulceroglandular Tularemia
- Ulcer develops at site of inoculation with tender lymphadenopathy and systemic symptoms
Glandular Tularemia
- Ulcer is undetectable or healed, only lymphadenopathy and systemic illness remains
Oculoglandular Tularemia
- Entry through the conjuctiva
- Rare
Pharyngeal Tularemia
- Entry through the oropharynx, with exudative pharyngitis/tonsillitis
- May be difficult to distinguish from other forms of tularemia that also may have sore throat
Typhoidal Tularemia
- Febrile illness without lymphadenopathy or ulcer, sometimes with diarrhea
- Patient often has an underlying chronic disease
- Often rapidly-progressive and fatal
Pneumonic Tularemia
- Acquired by direct inhalation, often from sheep shearing, landscaping, and microbiology laboratory work
Diagnosis
- Culture
- Grows slowly on standard culture media, needs cystine-rich media (e.g. chocolate agar, BHI, or cystine media)
- Looks bacillary in logarithmic growth phase (small Gram-negative rod), slow-growing only on chocolate agar
- Serology (EIA) can be used in the right context
- PCR
Management
- For severe disease, streptomycin 10 mg/kg (max 1 g) IM q12h for 7 to 10 days
- Alternatives include gentamicin or amikacin
- For mild to moderate disease, alternatives include:
- Doxycycline 100 mg po bid for 14 to 21 days
- Ciprofloxacin 500 mg po bid for 10 to 14 days
- For meningitis, use an aminoglycoside (as above) plus either IV ciprofloxacin, doxycycline, or chloramphenicol for 14 to 21 days
- Aminoglycosides have poor CNS penetration
Prevention
Vaccination
- Live attenuated vaccine derived from holarctica
Lab Safety
- This is a biosafety risk group 3 organism
- Should be suspected with any slowly-growing, small, and poorly-staining Gram-negative coccobacillus is isolated on chocolate agar but not blood agar
- Automated laboratory identification systems should not be used, because the risk of aerosol generation
- Commonly misidentified by automated methods as Haemophilus or Aggregatibacter species